Viridian Therapeutics Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review

Reuters

2025/05/20

Viridian <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review

Viridian Therapeutics, Inc., a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced a significant milestone in the regulatory review process for its drug veligrotug. The company is on track to submit a Biologics License Application $(BLA.AU)$ for veligrotug, an anti-IGF-1R antibody developed for treating active thyroid eye disease (TED), in the second half of 2025. Veligrotug, which recently received Breakthrough Therapy Designation, is anticipated for a U.S. commercial launch in 2026, pending approval. This designation supports its eligibility for Priority Review due to its demonstrated effectiveness in improving and resolving symptoms of TED in clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250520329293) on May 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536619790"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536619790\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536619790?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536619790","market":"nz","top_or_hot":-1,"title":"Viridian Therapeutics Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Viridian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VRDN\">Viridian Therapeutics, Inc.</a>, a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced a significant milestone in the regulatory review process for its drug veligrotug. The company is on track to submit a Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> for veligrotug, an anti-IGF-1R antibody developed for treating active thyroid eye disease (TED), in the second half of 2025. Veligrotug, which recently received Breakthrough Therapy Designation, is anticipated for a U.S. commercial launch in 2026, pending approval. This designation supports its eligibility for Priority Review due to its demonstrated effectiveness in improving and resolving symptoms of TED in clinical trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250520329293) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viridian Therapeutics Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViridian Therapeutics Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-20 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Viridian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VRDN\">Viridian Therapeutics, Inc.</a>, a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced a significant milestone in the regulatory review process for its drug veligrotug. The company is on track to submit a Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> for veligrotug, an anti-IGF-1R antibody developed for treating active thyroid eye disease (TED), in the second half of 2025. Veligrotug, which recently received Breakthrough Therapy Designation, is anticipated for a U.S. commercial launch in 2026, pending approval. This designation supports its eligibility for Priority Review due to its demonstrated effectiveness in improving and resolving symptoms of TED in clinical trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250520329293) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRDN","symbol_name":"Viridian Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL4BNPQR:1","article_id":"2536619790","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536619790","pubTimestamp":1747738911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viridian Therapeutics, Inc., a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced a significant milestone in the regulatory review process for its drug veligrotug. The company is on track to submit a Biologics License Application  for veligrotug, an anti-IGF-1R antibody developed for treating active thyroid eye disease , in the second half of 2025. Veligrotug, which recently received Breakthrough Therapy Designation, is anticipated for a U.S. commercial launch in 2026, pending approval. This designation supports its eligibility for Priority Review due to its demonstrated effectiveness in improving and resolving symptoms of TED in clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRDN":"Viridian Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Viridian Therapeutics Inc.宣布Veligrotug突破性疗法认定，为优先审查铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRDN":0.9},"content_text":"Viridian Therapeutics Inc. Announces Breakthrough Therapy Designation for Veligrotug, Paving Way for Priority Review\n    \n\nViridian Therapeutics, Inc., a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced a significant milestone in the regulatory review process for its drug veligrotug. The company is on track to submit a Biologics License Application $(BLA.AU)$ for veligrotug, an anti-IGF-1R antibody developed for treating active thyroid eye disease (TED), in the second half of 2025. Veligrotug, which recently received Breakthrough Therapy Designation, is anticipated for a U.S. commercial launch in 2026, pending approval. This designation supports its eligibility for Priority Review due to its demonstrated effectiveness in improving and resolving symptoms of TED in clinical trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250520329293) on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}